Condition
NF2
Total Trials
5
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Early P 1 (1)
P 1 (2)
P 2 (2)
Trial Status
Not Yet Recruiting4
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07713745Phase 2Not Yet Recruiting
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
NCT07708285Phase 1Not Yet Recruiting
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
NCT07707947Phase 2Not Yet Recruiting
Selumetinib for NF2-Related Schwannomatosis
NCT07131722Phase 1Not Yet Recruiting
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II
NCT00863122Early Phase 1Completed
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Showing all 5 trials